Impact of Time Restricted Feeding on Daily Protein Requirements

NCT ID: NCT05610644

Last Updated: 2024-12-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-29

Study Completion Date

2024-10-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to assess 24-hour protein kinetics at two different levels of protein intake: 0.8 (RDA) and 1.6g/kg/day (2RDA) during a normal dietary (TRAD) and a time restricted feeding (TRF) pattern in older adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators aim to assess 24-hour protein kinetics at two different levels of protein intake: 0.8 (RDA) and 1.6g/kg/day (2RDA) during a normal dietary (TRAD) and a time restricted feeding (TRF) pattern in older adults. Individuals in the TRF pattern will only consume food during a 6-hour eating period and fast for the remaining 18 hours. Individuals in the TRAD pattern will consume isocaloric and isonitrogenous (RDA or 2RDA) diet but consume an all-beef-breakfast. Participants will consume oral stable isotopes to measure muscle protein synthesis (MPS), whole-body muscle protein breakdown (MPB), and whole-body protein balance (WBPB). Appropriate muscle, blood samples, and urine will be collected throughout a 24-hour metabolic trial following a 2-day controlled diet.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nutrition Disorders in Old Age

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TRF of RDA

A time-restricted model of consumption of the RDA of protein/day.

Group Type ACTIVE_COMPARATOR

isocaloric, isonitrogenous meals

Intervention Type OTHER

Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.

TRAD of RDA

A typical American dietary ingestion pattern of the RDA of protein/day.

Group Type ACTIVE_COMPARATOR

isocaloric, isonitrogenous meals

Intervention Type OTHER

Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.

TRF of 2RDA

A time-restricted model of consumption of twice the RDA of protein/day.

Group Type EXPERIMENTAL

isocaloric, isonitrogenous meals

Intervention Type OTHER

Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.

TRAD of 2RDA

A typical American dietary ingestion pattern of twice the RDA of protein/day.

Group Type EXPERIMENTAL

isocaloric, isonitrogenous meals

Intervention Type OTHER

Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

isocaloric, isonitrogenous meals

Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men and women ages 50-75 years.
2. BMI 20-30 kg/m2 inclusive.
3. Capable of providing informed consent.
4. COVID-19 negative and/or asymptomatic

Exclusion Criteria

1. Subject who does not/will not eat animal protein sources.
2. Body mass index \<20 or \>30.
3. Hemoglobin \<10g/dL at screening.
4. Platelets \<150,000/uL at screening.
5. History of diabetes.
6. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment.
7. History of gastrointestinal bypass/reduction surgery.
8. History of a chronic inflammatory disease (e.g. what?)
9. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy.
10. Currently using prescription blood thinning medications.
11. Currently using corticosteroid medications.
12. Unable or unwilling to suspend aspirin use for 7 days prior to Visit 3.
13. Unwilling to avoid using protein or amino-acid supplements during participation.
14. Subjects who are unwilling to fast overnight.
15. Participating in \>200 minutes/week of vigorous exercise and/or \>4 days/week of resistance training.
Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Arkansas

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Church

Role: PRINCIPAL_INVESTIGATOR

UAMS (University of Arkansas for Medical Sciences)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

275081

Identifier Type: -

Identifier Source: org_study_id